+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2019

  • ID: 4866593
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 58 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Emergent BioSolutions Inc
  • Etubics Corp
  • GeoVax Labs Inc
  • Kineta Inc
  • Medigen Inc
  • RetroVirox Inc
  • MORE
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever - Pipeline Review, H2 2019, provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape.

Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arena virus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Lassa Fever - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Lassa Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lassa Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Lassa Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Lassa Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lassa Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lassa Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lassa Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Emergent BioSolutions Inc
  • Etubics Corp
  • GeoVax Labs Inc
  • Kineta Inc
  • Medigen Inc
  • RetroVirox Inc
  • MORE
Introduction
Report Coverage
Lassa Fever (Lassa Hemorrhagic Fever) - Overview
Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development
Emergent BioSolutions Inc
Etubics Corp
Fujifilm Toyama Chemical Co Ltd
GeoVax Labs Inc
Inovio Pharmaceuticals Inc
Kineta Inc
Medigen Inc
RetroVirox Inc
Themis Bioscience GmbH
Zalgen Labs LLC
Lassa Fever (Lassa Hemorrhagic Fever) - Drug Profiles
(Lassa fever + rabies) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arevirumab-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
favipiravir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GEOLM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hemorrhagic fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-4500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lassa vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LHF-535 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ML-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Lassa Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-193 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects
Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones
Featured News & Press Releases
Oct 30, 2019: Themis Bioscience and CEPI trial Lassa fever vaccine
Aug 06, 2019: Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535
Jul 16, 2019: GeoVax announces upcoming presentation of lassa fever vaccine data
Jul 15, 2019: Kineta secures NIAID grant worth up to $5.8M to evaluate LHF-535 in Arenaviruses
May 23, 2019: Inovio doses patients in Phase I trial of Lassa virus vaccine INO-4500
Dec 11, 2018: Batavia Biosciences Partners with IAVI to Advance Development of Vaccine Against Lassa Fever
Sep 26, 2018: GeoVax awarded $2.4 million from U.S. Department of Defense to advance Lassa Fever Vaccine
Sep 05, 2018: Kineta initiates first-in-human clinical trial of LHF-535 a novel therapy for lassa fever
Aug 20, 2018: Emergent and Profectus receive CEPI contract for Lassa virus vaccine
Jun 27, 2018: NIAID Scientists Recommend Favipiravir for Human Trials of Lassa Fever Virus
Apr 10, 2018: GeoVax Awarded NIH Fast Track Phase I/II Grant to Advance Lassa Fever Vaccine
Oct 24, 2017: Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
Jul 24, 2017: GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine
Jul 11, 2017: Tulane University awarded $12 million to create Lassa vaccine and treatment
Jul 10, 2017: GeoVax Reports Promising Results for Lassa Fever Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2019
Table 11: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Etubics Corp, H2 2019
Table 12: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Fujifilm Toyama Chemical Co Ltd, H2 2019
Table 13: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, H2 2019
Table 14: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Table 15: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Kineta Inc, H2 2019
Table 16: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Medigen Inc, H2 2019
Table 17: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by RetroVirox Inc, H2 2019
Table 18: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Themis Bioscience GmbH, H2 2019
Table 19: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Zalgen Labs LLC, H2 2019
Table 20: Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects, H2 2019

List of Figures
Figure 1: Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Targets, H2 2019
Figure 6: Number of Products by Routes of Administration, H2 2019
Figure 7: Number of Products by Stage and Routes of Administration, H2 2019
Figure 8: Number of Products by Molecule Types, H2 2019
Figure 9: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Emergent BioSolutions Inc
  • Etubics Corp
  • Fujifilm Toyama Chemical Co Ltd
  • GeoVax Labs Inc
  • Inovio Pharmaceuticals Inc
  • Kineta Inc
  • Medigen Inc
  • RetroVirox Inc
  • Themis Bioscience GmbH
  • Zalgen Labs LLC
Note: Product cover images may vary from those shown
Adroll
adroll